GlassScriptPhysician profile
Douglas D Hage
NPI 1538113873
$5,520.06
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $847 · 2021: $1,032 · 2022: $923 · 2023: $1,430 · 2024: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.81 |
| Education | $176.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.01 | 2019-2023 | |
| Pfizer INC. | $791.11 | 2019-2023 | |
| Avion Pharmaceuticals | $463.95 | 2019-2021 | |
| Astellas Pharma US INC | $436.13 | 2023-2024 | Veozah, Myrbetriq |
| Therapeuticsmd, INC. | $380.03 | 2019-2022 | |
| Agile Therapeutics, INC. | $317.10 | 2021-2024 | Twirla |
| Amgen INC. | $300.73 | 2019-2023 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $296.20 | 2022-2024 | |
| Exeltis, USA INC. | $186.46 | 2022-2024 | Slynd |
| Daiichi Sankyo INC. | $172.51 | 2020-2024 | Injectafer |
| Myovant Sciences INC. | $143.14 | 2021-2022 | |
| Mckesson Patient Care Solutions INC. | $117.82 | 2019 | |
| Sumitomo Pharma America, INC. | $104.98 | 2023 | Myfembree |
| Amag Pharmaceuticals, INC. | $74.96 | 2019-2020 | |
| Novo Nordisk INC | $70.56 | 2023-2024 | Wegovy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $62.12 | 2022 | |
| Millicent US INC | $57.85 | 2019-2021 | |
| Exact Sciences Corporation | $46.73 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $45.80 | 2023-2024 | Accrufer |
| Medicem INC. | $44.63 | 2020-2021 | |
| Mycovia Pharmaceuticals, INC. | $25.63 | 2023 | Vivjoa |
| Smith+Nephew, INC. | $23.22 | 2023 | Oasis, Grafix Pl |
| Hologic Sales and Service, LLC | $20.62 | 2024 | Aptima |
| Vertical Pharmaceuticals, LLC | $17.89 | 2019 | |
| Roche Diagnostics Corporation | $15.36 | 2021 | |
| Meditrina | $13.94 | 2022 | |
| Allergan, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Hage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.